Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dclonom-TH
- Development stage
- Phase 4
- Lead developer
- Acinom Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dclonom-TH is a small molecule combination drug developed and manufactured by Acinom Healthcare, an Indian pharmaceutical company. It is a generic formulation typically composed of diclofenac, a non-steroidal anti-inflammatory drug (NSAID), and thiocolchicoside, a muscle relaxant. Diclofenac provides analgesic and anti-inflammatory effects by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the production of prostaglandins that mediate pain and inflammation. Thiocolchicoside is a semi-synthetic derivative of colchicoside that acts as a competitive gamma-aminobutyric acid (GABA) receptor antagonist and also exhibits glycine receptor antagonism. Despite its antagonistic pharmacological profile, it functions as a muscle relaxant to treat painful muscle spasms. Dclonom-TH is primarily used for the management of acute pain and inflammation associated with musculoskeletal disorders such as low back pain, neck pain, and post-traumatic conditions.
- Brand names
- Dclonom-THDclonom-T
- Other names
- diclofenac + thiocolchicoside
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GABRR (GABA-A receptor subunit rho)Glycine receptorα4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)
Beyond the preview
Go deeper on Dclonom-TH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dclonom-TH.